Ayisha Sharma

For the first time since 2018, der­ma­tol­ogy-fo­cused Leo Phar­ma projects that it could turn a prof­it this year. Its Wednes­day guid­ance comes on the heels

Sanofi and Te­va’s in­flam­ma­to­ry bow­el dis­ease can­di­date could make €1 bil­lion ($1.05 bil­lion) a year by 2032, Leerink an­a­lysts said on Sun­day. The block­buster pro­jec­tion

Epi­to­pea has inked a li­cense and re­search col­lab­o­ra­tion with Mer­ck to dis­cov­er new tu­mor-spe­cif­ic anti­gens from so-called “dark mat­ter” DNA, which are parts of the

Al­go­Ther­a­peu­tix’s top­i­cal non-opi­oid drug has flunked a mid-stage tri­al in chemother­a­py-in­duced pain due to a stronger-than-ex­pect­ed place­bo arm, but the com­pa­ny is still de­ter­mined to

Cor­bus Phar­ma­ceu­ti­cals re­port­ed en­cour­ag­ing ear­ly-stage re­sults for its Nectin-4 tar­get­ing ADC in var­i­ous types of can­cer, but a lack of re­sponse in cer­tain pa­tients caused

Bris­tol My­ers Squibb’s LAG-3/PD-1 tar­get­ing im­munother­a­py Op­du­alag failed to boost sur­vival in pa­tients with ad­vanced skin can­cer in a Phase 3 study, mark­ing the lat­est